Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- James K Mangan, M.D., P.h.D.
University of California, San Diego
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ucsf Fresno Community Cancer Institute
Clovis, California, United States
- Uc San Diego Moores Cancer Center
La Jolla, California, United States
- Uc Irvine Health Chao Family Comprehensive Cancer Center
Orange, California, United States
- Ucsf Comprehensive Cancer Center
San Francisco, California, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Aug 2017
- Primary completion
- 21 Dec 2021
- Completion
- 23 Jun 2023
- Last update posted
- 10 Nov 2025
- Registered enrollment
- 16
- Registry id
- NCT03160079
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.